Page last updated: 2024-10-15

amg531

Cross-References

ID SourceID
PubMed CID135449332
CHEMBL ID461101
CHEMBL ID478463
CHEMBL ID3186485
CHEBI ID85010
SCHEMBL ID211082
SCHEMBL ID211081
SCHEMBL ID18910
SCHEMBL ID164270
MeSH IDM0471611

Synonyms (103)

Synonym
sb-497115
bdbm50248106
eltrombopag ,
496775-61-2
sb497115
CHEMBL461101 ,
chebi:85010 ,
(z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
FT-0660417
A25156
sb 497115; sb497115gr;3'-[2-[(2z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
EX-7216
(z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxy-[1,
CHEMBL478463
3'-{(2z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid
3'-{(2z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid
amg531
BCP9000641
3'-[2-[(2z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
AKOS015920246
s56d65xj9g ,
eltrombopag [inn]
unii-s56d65xj9g
hsdb 8212
sb-497 115
(1,1'-biphenyl)-3-carboxylic acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-
S4502
BCPP000243
eltrombopag [mi]
(1,1'-biphenyl)-3-carboxylic acid, 3'-(2-(1-(3,4-dimethylphenyl)-4,5-dihydro-3-methyl-5-oxo-1h-pyrazol-4-yl)diazenyl)-2'-hydroxy-
376591-99-0
eltrombopag [ema epar]
3'-((2z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic acid
eltrombopag [vandf]
eltrombopag [mart.]
eltrombopag [who-dd]
sb 497115
gtpl6961
3-(3-{2-[(4z)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1h-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid
SCHEMBL211082
SCHEMBL211081
DB06210
HY-15306
CS-1565
smr004701208
MLS006010024
SCHEMBL18910
SCHEMBL164270
NCGC00274067-01
cas-496775-61-2
dtxcid6031542
dtxsid5057753 ,
tox21_113965
AB01274808-01
XDXWLKQMMKQXPV-UHFFFAOYSA-N
3'-{n'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid
3'-[(2z)- [1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
XDXWLKQMMKQXPV-QYQHSDTDSA-N
(z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxybiphenyl-3-carboxylic acid
CHEMBL3186485
AB01274808_02
eltrombopag (sb-497115-gr)
AKOS026750537
EX-A443
1807882-48-9
AKOS030524935
HMS3655B14
3'-{n'-[1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid
(z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
SW219608-1
sb-497115-gr;sb497115
3'-{(2z)-2-(1-[3,4-dimethylphenyl]-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid
Q411588
eltrombopag free base
496775-61-2 (free base)
AS-35176
(e)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
AS-19180
3'-{2-[(4e)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1h-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
BCP01884
AMY10836
SB19101
3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1h-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
mfcd20926253
HMS3743O17
CCG-269152
C75316
(ze)-eltrombopag
3-[2-[(2z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinyl]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid
3-[(5e)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1h-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid
AKOS037515498
NCGC00274067-02
eltrombopag- bio-x
BE164406
3-[(5e)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1h-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid
EN300-23586760
EN300-260743
3'-{2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1h-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
EN300-1709152
3-[(5z)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1h-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid
Z2568748600

Toxicity

ExcerptReference
" There was no notable difference in adverse event frequency across eltrombopag doses."( Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Bowen, C; Jenkins, J; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB, 2011
)
" The most commonly reported adverse events across all study arms (including placebo) were nausea and alopecia and eltrombopag was generally well tolerated."( A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Bondarenko, IN; Jagiello-Gruszfeld, A; Kellum, A; Messam, C; Mostafa Kamel, Y; Patwardhan, R, 2010
)
" Most adverse events reported were grade 1 or 2; 2 patients in the 37."( Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H, 2012
)
" Thirty-eight patients (13%) experienced ≥ 1 adverse events leading to study withdrawal, including patients meeting protocol-defined withdrawal criteria (11 [4%] thromboembolic events, 5 [2%] exceeding liver enzyme thresholds)."( Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Arning, M; Bailey, CK; Brainsky, A; Bussel, JB; Cheng, G; Meyer, O; Saleh, MN, 2013
)
" Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation."( Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Hattori, T; Ikeda, Y; Ishii, K; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Okamoto, S; Okoshi, Y; Tomiyama, Y, 2013
)
"Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS)."( A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T, 2014
)
" Severe adverse events included infectious complications, deep vein thrombosis and transient ischaemic attack."( A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T, 2014
)
" Hepatotoxicity and all other adverse events were mild and manageable."( Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Eser, A; Firatli-Tuglular, T; Kara, O; Kaygusuz-Atagunduz, I; Noyan-Atalay, F; Ozgumus, T; Pepedil-Tanrikulu, F; Sezgin, A; Toptas, T; Yilmaz, G, 2016
)
" The primary endpoint was safety and tolerability, including adverse events, non-haematological laboratory grade 3-4 toxic effects, and changes in bone-marrow blast counts from baseline."( Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP, 2015
)
" 63 (98%) patients in the eltrombopag group and 32 (94%) patients in the placebo group had adverse events."( Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP, 2015
)
"Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP)."( Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Aguilar, C; Alvarez-Román, MT; Andrade, MM; Bárez, A; Bernat, S; Cortés, M; de Cabo, E; Fernández-Fuentes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Jarque, I; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Crespo, S; Pérez-Rus, G; Sánchez-González, B, 2016
)
"4%) experienced adverse events, mainly grades 1-2."( Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Aguilar, C; Alvarez-Román, MT; Andrade, MM; Bárez, A; Bernat, S; Cortés, M; de Cabo, E; Fernández-Fuentes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Jarque, I; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Crespo, S; Pérez-Rus, G; Sánchez-González, B, 2016
)
" This report reviews the mechanism and use of eltrombopag along with a summary of associated adverse cutaneous reactions."( Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi, T; Martin, S; Worswick, S, 2016
)
"Eltrombopag is safe and effective in primary chronic ITP."( Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
Aguilar, C; Alvarez-Román, MT; Arrieta-Cerdán, E; Bárez, A; Bernat, S; de Cabo, E; Fernández-Fuertes, F; Fernández-Rodríguez, A; García-Frade, LJ; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Rus, G; Sánchez-González, B, 2017
)
" This study quantifies and compares adverse event (AE) crude rates and costs associated with ITP treatments as found in claims data."( Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Babinchak, T; Bilir, SP; Donga, PZ; Little, G; Munakata, J, 2017
)
" Conclusions This case series suggests that TPO mimetics are safe and moderately effective in patients with ITP in the setting of SLE or APS and do not contribute to increased disease activity."( Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Carlson, A; Lusa, A, 2018
)
" However, clone evolution and adverse events were associated with treatment."( Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Chen, Y; Hong, Y; Li, N; Li, X; Wan, B, 2019
)
" Most patients demonstrated a long-term stable effect in the form of an increase in blood platelet count to a safe level during months and years of ATR treatment."( Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Arshanskaya, EG; Chernikov, MV; Pankrashkina, MM; Ptushkin, VV; Tkachenko, NE; Vinogradova, OY, 2018
)
"Long-term ATR-therapy using in patients with resistant chronic ITP is an effective and largely safe treatment option."( Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Arshanskaya, EG; Chernikov, MV; Pankrashkina, MM; Ptushkin, VV; Tkachenko, NE; Vinogradova, OY, 2018
)
" Time taken for response to therapy (defined as platelets >1 lakh), dose, duration of treatment, and adverse effects of the drug were noted."( Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia.
Roongta, R; Sanil, S; Shobha, V, 2020
)
" No adverse events including thrombotic complication were noted."( Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia.
Roongta, R; Sanil, S; Shobha, V, 2020
)
" It indirectly contributes to reduction in the dose of steroids and immunosuppressants, thereby minimizing their cumulative adverse effects."( Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia.
Roongta, R; Sanil, S; Shobha, V, 2020
)
" Treatment response rates, durable response rates, bleeding events, and adverse events were assessed during eltrombopag therapy for at least 12 weeks."( Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study.
Chen, Z; Cheng, X; Ma, J; Wang, X; Wu, R; Yan, K; Zhao, L,
)
" Initial response rate, durable response rate, bleeding events, and adverse events were assessed during the follow-up period."( Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Chen, M; Fang, JP; Li, XY; Lin, SF; Xu, LH; Zhou, CX, 2021
)
" No serious bleeding events or serious adverse events occurred during the study period."( Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Chen, M; Fang, JP; Li, XY; Lin, SF; Xu, LH; Zhou, CX, 2021
)
" Eltrombopag was well-tolerated; however, the most common adverse events included indirect bilirubin elevation, jaundice, and transient liver-enzyme elevation."( Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Cheng, X; Fu, L; He, Y; Jie, M; Li, S; Wu, R; Yao, J; Zhang, L; Zhang, R; Zheng, J, 2021
)
" This study aimed to assess the relationship between eltrombopag and thrombotic events in a large population extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) database."( Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
Jiang, JJ; Li, J; Zhao, B, 2022
)
" There were no significant associations between genotypes and adverse drug reactions (ADRs) or ELT concentrations and ADRs."( Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia.
Chen, M; Han, B; Liu, B; Zhang, B; Zuo, W, 2022
)
"The aim of the study was to conduct a network meta-analysis to assess the efficacy and incidence of treatment-related adverse events (TRAEs) of eltrombopag, romiplostim, avatrombopag, recombinant human thrombopoietin (rhTPO), and hetrombopag for adult immune thrombocytopenia (ITP)."( Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Feng, CX; Geng, QC; Lin, X; Liu, Y; Su, J; Zhang, HX, 2023
)
" We aimed to evaluate the safety of the TPORAs romiplostim and eltrombopag using data from the Adverse Event Reporting System database of FDA (FAERS)."( Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database.
Chen, Y; Fang, Q; Huang, F; Li, C; Liang, J; Luo, W; Wu, X; Zhang, M,
)
"We conducted a disproportionality analysis and analyzed data from the FAERS database to characterize the key features of adverse events (AEs) associated with TPO-RAs approved for children under 18 years of age."( Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database.
Chen, Y; Fang, Q; Huang, F; Li, C; Liang, J; Luo, W; Wu, X; Zhang, M,
)
" The results of meta-analysis showed that in adult patients, patients treated with TPO-RAs had longer duration of platelet response, higher platelet response rate, lower use of rescue therapy, and lower incidence of bleeding events, and similar incidence of adverse events compared with placebo."( Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Li, T; Liu, J; Liu, Q; Pu, T; Zhang, A, 2023
)
" This study aimed to explore the clinical features of adverse drug events (ADEs) associated with eltrombopag in different age groups using individual case safety reports (ICSRs) from the World Health Organization database VigiBase and the US Food and Drug Administration Adverse Event Reporting System database from 2008 to 2022 in combination with a meta-analysis of data from randomized clinical trials in the literature from inception to July 28, 2022."( Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials.
Fan, G; Feng, T; Lou, Y; Ma, C; Qiaolongbatu, X; Qu, H; Song, X; Wu, J; Wu, Z, 2023
)

Pharmacokinetics

ExcerptReference
"The aim of these studies was to assess the effect of food and antacids on the pharmacokinetic and safety profiles of eltrombopag."( Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Bailey, CK; Collins, DA; Deng, Y; Jenkins, JM; Kapsi, SG; Park, JW; Peng, B; Williams, DD; Wire, MB, 2009
)
" There was high pharmacokinetic variability and significant overlap in exposures between participants with hepatic or renal impairment and healthy participants."( Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman, JW; Park, JW; Peng, B; Vincent, CT; Williams, DD; Wire, MB, 2011
)
" Previous reports indicate that ELT is mainly eliminated in the liver, although its pharmacokinetic profile has not yet been clarified in detail."( Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
Horikawa, M; Ishiwata, N; Kato, Y; Matsubara, K; Nakamichi, N; Silver, DL; Sugiura, T; Takeuchi, K; Umeda, S, 2011
)
" Noncompartmental pharmacokinetic parameters were estimated from plasma concentration-time data collected over 72 hours post-dose."( A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB, 2012
)
" The proposed method was found to be applicable to pharmacokinetic studies."( Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study.
Gajula, R; Maddela, R; Maddela, S; Makula, A; Pilli, NR; Siddiraju, S, 2014
)
"This study characterized the population pharmacokinetic (pop-PK) and PK/pharmacodynamic (pop-PK/PD) properties of eltrombopag and evaluated platelet count (PLTC) response to different eltrombopag dosages through simulations in Chinese adult patients with chronic primary immune thrombocytopenia (cITP)."( Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Farrell, C; Guo, H; Hayes, S; Hou, M; Thapar, M; Wu, K; Zhang, J, 2015
)
" Bayesian statistical approach will be applied to screen for patients' characteristics associated with eltrombopag pharmacokinetic parameters."( Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI, 2019
)
"A two-compartment pharmacokinetic model with first-order absorption with exponential error model best fit the data."( Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI, 2019
)
"Eltrombopag pharmacokinetic behavior was described using population bayesian approach."( Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI, 2019
)
"Sex and CYP1A2 rs762551 C>A were associated with the pharmacokinetic variability of eltrombopag in healthy Chinese subjects."( Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.
Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y; Yang, D, 2021
)

Compound-Compound Interactions

ExcerptReference
" A semimechanistic physiologically-based pharmacokinetic (PBPK) model was developed to evaluate the potential for clinical drug-drug interactions (DDIs)."( Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models.
Carter, SJ; Chappell, MJ; Chouhan, B; Sharma, P, 2020
)
" This study assessed the efficacy and safety of eltrombopag in combination with rabbit-ATG/CsA in IST-naïve patients with non-severe or severe AA in Japan."( Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Fanghong, Z; Hombo, Y; Iida, H; Imada, K; Imajo, K; Kumagai, A; Maeda, T; Matsuda, A; Nakao, S; Obara, N; Tajima, T; Usuki, K, 2021
)
" In recent trials, eltrombopag combined with standard immunosuppressive therapy yielded superior responses than those to immunosuppressive therapy alone."( Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
Feng, X; Groarke, EM; Patel, BA; Shalhoub, R; Wu, CO; Young, NS; Zaimoku, Y, 2022
)
"When it comes to the treatment of aplastic anemia fever, the Guidelines for Aplastic Anemia regards Anti-thymocyte globulin (ATG) combined with eltrombopag as the standard immunosuppressive treatment plan, and ATG is the main mode to treat severe aplastic anemia."( A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Chen, L; Han, S; Liu, J; Peng, Y; Wang, H; Wu, Y; Zhang, J, 2021
)
" Patients in the experimental group were administered ATG combined with eltrombopag and patients in the control group received ATG treatment alone."( A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Chen, L; Han, S; Liu, J; Peng, Y; Wang, H; Wu, Y; Zhang, J, 2021
)
" Therefore, we sought to explore the synergistic effects and possible mechanisms of DFX combination with ELT in MDS cells."( Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M, 2022
)
" Therefore, we performed rituximab combined with a low dose of EPAG."( Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.
Bao, X; Ji, C; Yuan, C; Zhang, N, 2022
)
"The patient received 2 cycles of rituximab combined with EPAG, and reported no new petechiae on her buccal mucosa and limbs during follow-up."( Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.
Bao, X; Ji, C; Yuan, C; Zhang, N, 2022
)
"This case suggests that early treatment of rituximab combined with EPAG is beneficial to patients with refractory ITP in RA."( Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.
Bao, X; Ji, C; Yuan, C; Zhang, N, 2022
)

Bioavailability

ExcerptReference
"4 microM high throughput screen hit, members of this series have been identified which are full agonists with functional potency <50 nM and oral bioavailability in mice."( Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.
Alper, PB; Chang, J; Chatterjee, A; Chow, D; Gerken, A; Gordon, P; He, Y; Karanewsky, DS; Lao, J; Liu, B; Lu, W; Marsilje, TH; Mutnick, D; Roberts, MJ; Seidel, HM; Tian, SS; Tuntland, T, 2008
)
" Preclinical testing on healthy volunteers shows high drug bioavailability and efficacy in raising platelet counts."( Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Eisert, C; Makarov, L; Sabaeva, E; Serebruany, VL,
)
"We aimed to assess the bioavailability of eltrombopag PfOS relative to the tablet formulation and the effect of a high-calcium meal on PfOS bioavailability."( A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB, 2012
)
"In a healthy adult volunteer population, bioavailability of eltrombopag PfOS was greater than the tablet and was reduced when administered with or 2 hours before or after a high-calcium meal; this effect was attenuated with PfOS dosing 2 hours before the meal."( A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB, 2012
)
"Eltrombopag is an orally bioavailable thrombopoietin receptor agonist that is approved for the treatment of chronic idiopathic thrombocytopenic purpura."( Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
McLean, HB; Park, JW; Pendry, C; Peng, B; Theodore, D; Wire, MB, 2012
)
" While romiplostim was the first second generation thrombopoietin agonist to become available, eltrombopag is particularly attractive as it is an orally bioavailable agent."( Eltrombopag--an oral thrombopoietin agonist.
Aggarwal, S; Randhawa, H; Sharma, A; Sharma, V, 2012
)
"Eltrombopag is an orally bioavailable thrombopoietin receptor agonist approved for the treatment of thrombocytopenia associated with chronic immune (idiopathic) thrombocytopenic purpura and chronic hepatitis C virus (HCV) infection."( Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB, 2014
)
" However, factors such as changes of pharmacokinetics might modulate the effects of eltrombopag in older patients in Japan because East Asians show higher bioavailability of eltrombopag by as-yet-unknown mechanisms."( Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
Arai, N; Ariizumi, H; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Mori, H; Nakamaki, T; Saito, B; Shiozawa, E; Tsukamoto, H; Uto, Y; Yanagisawa, K, 2015
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
"Eltrombopag is an orally bioavailable drug developed as a second-line treatment for immune thrombocytopenia."( Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
Jiang, JJ; Li, J; Zhao, B, 2022
)

Dosage Studied

ExcerptReference
" A small-molecule thrombopoietin mimetic, eltrombo-pag, has demonstrated a dose-response associated increase in platelet count in a phase 2 study, allowing initiation and completion of a 12-week course of peginterferon plus ribavirin in 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, or 75 mg of eltrombopag daily, respectively, compared with 6% in the placebo arm."( Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
McHutchison, JG; Patel, K; Tillmann, HL, 2009
)
" Plasma eltrombopag concentrations accumulated between days 1 and 5, with average increases of 66% to 81% for area under the plasma concentration-time curve from time zero to the end of the 24-hour dosing interval (AUC(0-τ)) and 32% to 45% for maximum observed plasma concentration (C(max)) across doses."( Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Bowen, C; Jenkins, J; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB, 2011
)
" When deciding which of these agents to prescribe, considerations include oral versus injectable dosage form, adverse-event profiles, and patient adherence with both taking the drug and keeping clinic appointments for monitoring of platelet counts."( Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan, JD; Herrington, JD, 2010
)
" In the ongoing open-label extension study, Eltrombopag EXTENDed Dosing Study (EXTEND; n = 154), measures were administered at baseline, at the beginning of each stage, and at permanent discontinuation of study medication."( Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.
Brainsky, A; Grotzinger, KM; Signorovitch, J, 2011
)
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
" The absorption lag time and t(½) did not differ between treatments; T(max) was delayed 1 hour when the PfOS was dosed with a high-calcium meal."( A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB, 2012
)
"In a healthy adult volunteer population, bioavailability of eltrombopag PfOS was greater than the tablet and was reduced when administered with or 2 hours before or after a high-calcium meal; this effect was attenuated with PfOS dosing 2 hours before the meal."( A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB, 2012
)
" This open-label, single-arm study evaluated consistency of response and safety following repeated intermittent dosing of eltrombopag 50 mg daily over 3 cycles (1 cycle = up to 6 weeks on therapy followed by up to 4 weeks off therapy)."( Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Arning, M; Bussel, JB; Mayer, B; Saleh, MN; Stone, NL; Vasey, SY, 2013
)
"Patients aged 18 or older with histologically confirmed, locally advanced or metastatic STS were treated with 1 cycle of AI followed by AI with eltrombopag starting at Cycle 2, using 2 different dosing schedules."( Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013
)
" Available data suggest a potential pre- and post-chemotherapy dosing scheme for eltrombopag when administered with AI chemotherapy, and support further investigation of eltrombopag treatment in patients with chemotherapy-induced thrombocytopenia."( Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013
)
" Due to the delay in platelet response after the administration of eltrombopag or chemotherapy, a modeling and simulation approach was used to optimize the eltrombopag dosing regimen."( Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D, 2013
)
" Alternative eltrombopag dosing regimens were then simulated."( Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D, 2013
)
"Simulations indicated that eltrombopag administered 5 days before and 5 days after chemotherapy minimizes the decrease and fluctuations in platelet counts relative to other evaluated dosing regimens."( Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D, 2013
)
" Patients received eltrombopag once daily at the last dosage received in the prior study (12."( Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Hattori, T; Ikeda, Y; Ishii, K; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Okamoto, S; Okoshi, Y; Tomiyama, Y, 2013
)
" Eltrombopag was examined at dosage levels of 75, 150, 225, and 300 mg given orally once daily for 27 days, starting at 24 to 48 hours post-transplantation."( A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Andolina, JR; Becker, M; Chen, Y; Constine, LS; Dawson, KL; DeBolt, J; Erickson-Miller, CL; Friedberg, J; Hyrien, O; Johnson, BM; Liesveld, JL; Milner, LA; Phillips, GL; Smudzin, T, 2013
)
" The dosing was as follows: period 1, single 200-mg dose of eltrombopag; period 2, 800 mg boceprevir or 750 mg telaprevir every 8 hours (q8h) for 10 days; and period 3, single 200-mg dose of eltrombopag with either 800 mg boceprevir or 750 mg telaprevir q8h (3 doses)."( Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB, 2014
)
" Alemtuzumab and eltrombopag have been studied for treatment of AA; recruiting is ongoing in clinical trials to assess the appropriate dosing strategy and place in therapy."( Recent developments in drug therapy for aplastic anemia.
Bryan, J; Kadia, TM; Rexwinkle, A; Willis, L, 2014
)
"The pharmacokinetics of eltrombopag and its stimulation of platelet production were characterized in patients with chronic hepatitis C virus (HCV) infection to optimize an eltrombopag dosing regimen for treatment of HCV-related thrombocytopenia before and throughout peginterferon (pegIFN)-based antiviral therapy."( Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Farrell, C; Thapar, M; Wire, MB; Zhang, J, 2015
)
" Simulations were conducted using various dosing scenarios in the same patient population."( Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Farrell, C; Thapar, M; Wire, MB; Zhang, J, 2015
)
"Modeling and simulation results support once-daily eltrombopag 25 mg as an appropriate starting dosing regimen followed by biweekly dose escalation (in 25-mg increments) up to once-daily eltrombopag 100 mg to raise platelet counts sufficiently for initiation of pegIFN-based antiviral therapy in patients with HCV."( Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Farrell, C; Thapar, M; Wire, MB; Zhang, J, 2015
)
" Dosing patterns were also analyzed before and after switching."( Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Dawson, KL; Grotzinger, KM; Kuter, DJ; Macahilig, C; Poston, SA; Wang, PF; Ward, M, 2015
)
" Patients with chronic immune thrombocytopenia participating in the Eltrombopag Extended Dosing (EXTEND) study underwent BM biopsies to identify clinically relevant BM fibrosis-related increases."( Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Bailey, CK; Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D, 2015
)
" The 25-mg once-daily dosage was associated with a more balanced response than were the 12."( Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Farrell, C; Guo, H; Hayes, S; Hou, M; Thapar, M; Wu, K; Zhang, J, 2015
)
" The modeling and simulation results support the eltrombopag dose-titration regimen, with 25 mg once daily as a starting dosage and a 2-week titration interval, in Chinese patients with cITP."( Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Farrell, C; Guo, H; Hayes, S; Hou, M; Thapar, M; Wu, K; Zhang, J, 2015
)
"492) and an increase in the percentage of administrated dosage (89."( [Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors].
Cerezuela Fuentes, P; García Coronel, M; García Lagunar, MH; Gutiérrez-Meca Maestre, DP; Martínez Ortiz, MJ; Martínez Penella, M, 2015
)
"This study aims to identify patient characteristics that predict effective eltrombopag dosage for the treatment of Hepatitis C virus (HCV)-related thrombocytopenia."( Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Anter, HA; Khanfar, AA; Obeidat, AR; Saleh, MI, 2015
)
" We permitted dose adjustments on the basis of platelet response up to a maximum dosage of 75 mg per day."( Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bailey, CK; Bakshi, KK; Blanchette, VS; Boayue, KB; Bussel, JB; Chagin, KD; Chan, GW; Connor, P; David, M; de Miguel, PG; Despotovic, JM; Grainger, JD; Iyengar, M; Krishnamurti, L; Lambert, MP; Marcello, LM; Matthews, DC; Sevilla, J; Theodore, D, 2015
)
" Only 40% of patients demonstrated a stable response with consistent dosing over time."( Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Bennett, C; Brown, T; Despotovic, J; Forbes, PW; Grace, RF; Haley, K; Klaassen, R; Lambert, MP; Neunert, C; Nottage, K; Pastore, Y; Shimano, K; Stine, K; Thompson, A, 2016
)
" This model can be applied to optimize eltrombopag dosing in order to reduce the incidence of thrombocytopenia in HCV-infected patient receiving interferon-based therapy."( Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI, 2019
)
"Eltrombopag, an oral thrombopoietin receptor agonist, is dosed daily to treat chronic immune thrombocytopenia (ITP)."( An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Al-Samkari, H; Kuter, DJ, 2018
)
" The dosage of eltrombopag varies from 25 mg every other day (qod) to 100 mg every day (qd) (median 75 mg qd) with the duration of 13 (3~23) months."( Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.
Chen, M; Han, B; Ruan, J; Yang, C; Zuo, W, 2020
)
" Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab."( Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.
Gu, C; Kong, D; Li, Y; Tian, H; Wang, Z; Wu, D; Yin, J; Yu, Z, 2022
)
" However, EPAG dosage and combinations remain to be optimized for AA of different severities."( Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Chan, FHY; Chan, KP; Chan, TSY; Hwang, YY; Kho, B; Kwong, YL; Lau, CK; Lau, CWP; Lau, GWN; Lau, JSM; Leung, KH; Lin, SY; Luk, YY; Mak, V; Sim, JPY; Yip, SF, 2022
)
" ATG was applied within 30 days after diagnosis, ATG dosage was suffificient (ATG/lymphocyte ≥2), and absolute reticulocyte count (ARC) was ≥30×109 /L at 6 months, indicated patients could get delayed response and benefifit from CsA maintenance."( Partial SAA patients benefit from delayed response of IST.
Fu, R; Liu, C; Shao, Z; Wang, C; Wang, T, 2023
)
"The aim of this article is to summarize the available evidence and present real-life experience on eltrombopag as second-line therapy in pediatric patients with ITP, with a focus on dosing and response to therapy as well as its tapering and discontinuation."( Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Borchiellini, A; Dufour, C; Farruggia, P; Giona, F; Giordano, P; Ladogana, S; Palumbo, G; Perrotta, S; Pession, A; Ramenghi, U; Russo, G; Spinelli, M; Zecca, M, 2023
)
"Patients preferred therapies delivered orally, dosed less frequently and without food restrictions."( Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Bastiaanse, M; Daykin-Pont, O; Eriksson, D; Geldman, E; Gerard Jansen, AJ; McDonald, V; Morgan, M; Newland, A; Prince, S; Wilson, K; Zwaginga, JJ, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency38.90180.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency34.67130.002541.796015,848.9004AID1347397
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency21.31383.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.77970.006038.004119,952.5996AID1159521; AID1159523
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency8.41270.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency18.83360.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.76410.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency13.92480.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552; AID1159553; AID1159555
farnesoid X nuclear receptorHomo sapiens (human)Potency11.88230.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.61800.000229.305416,493.5996AID1259248
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency6.23060.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.60110.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency29.84700.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency1.19860.023723.228263.5986AID743223
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency26.832519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency67.40010.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency17.13290.039147.5451146.8240AID1224845; AID1224896
heat shock protein beta-1Homo sapiens (human)Potency30.04500.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency2.63750.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency38.90180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Ki103.00000.55004.26507.4600AID1217063
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)Ki8.48000.53004.11578.4800AID1217113
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)21.52000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)17.10330.00022.45859.9600AID1803986; AID1804171; AID1805801
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)528.73700.00091.901410.0000AID1207494; AID1207523; AID1282019
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)237.35850.00033.64849.2000AID1207309; AID1207340
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki25.60000.08002.46889.8000AID1217062
Potassium voltage-gated channel subfamily D member 3Homo sapiens (human)IC50 (µMol)1,584.89001.40005.35009.3000AID1207429
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)3.10000.00401.966610.0000AID1873216
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki14.90000.04401.36305.0000AID1217112
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)8.91000.00304.11059.8200AID1803987
Thrombopoietin receptorHomo sapiens (human)EC50 (µMol)0.03800.03803.269010.0000AID349040; AID387558
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (158)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
neutrophil homeostasisThrombopoietin receptorHomo sapiens (human)
monocyte homeostasisThrombopoietin receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationThrombopoietin receptorHomo sapiens (human)
cellular response to hypoxiaThrombopoietin receptorHomo sapiens (human)
positive regulation of platelet formationThrombopoietin receptorHomo sapiens (human)
eosinophil homeostasisThrombopoietin receptorHomo sapiens (human)
basophil homeostasisThrombopoietin receptorHomo sapiens (human)
thrombopoietin-mediated signaling pathwayThrombopoietin receptorHomo sapiens (human)
immunoglobulin mediated immune responseThrombopoietin receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (88)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein bindingThrombopoietin receptorHomo sapiens (human)
thrombopoietin receptor activityThrombopoietin receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
A-type (transient outward) potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
metal ion bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 2B1 Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
Golgi apparatusThrombopoietin receptorHomo sapiens (human)
plasma membraneThrombopoietin receptorHomo sapiens (human)
cell surfaceThrombopoietin receptorHomo sapiens (human)
nuclear membraneThrombopoietin receptorHomo sapiens (human)
neuronal cell bodyThrombopoietin receptorHomo sapiens (human)
external side of plasma membraneThrombopoietin receptorHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
sarcolemmaPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
GABA-ergic synapsePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic specialization membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
dendritic spinePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay IDTitleYearJournalArticle
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1207309Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1217093Drug uptake in mouse hepatocytes at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217086Clearance in Sprague-Dawley rat bile with respect to plasma concentration at 1 mg/kg, iv for 72 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217089Tissue uptake clearance in Sprague-Dawley rat liver at 1 mg/kg, iv in presence of 20 mg/kg rifampicin (Rvb = 44.8 +/- 4.4 ml/h/kg)2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217103Drug uptake in mouse hepatocytes in presence of TPeA2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217098Drug uptake in mouse hepatocytes in presence of rotenone ATP depletor2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217072Drug excretion in Sprague-Dawley rat bile assessed as unchanged compound level at 1 mg/kg, iv for 72 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217102Drug uptake in mouse hepatocytes in presence of tetraethylammonium2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217073Drug excretion in Sprague-Dawley rat urine assessed as unchanged compound level at 1 mg/kg, iv for 72 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207463Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID1873216Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells membrane vesicles mediated transport of 3[H]-methotrexate for 5 mins using [3H]-methotrexate as substrate by radiometric scintillation analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1217104Drug uptake in mouse hepatocytes in presence of quinidine2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217062Inhibition of OATP1B3-mediated [3H]estradiol 17beta-glucuronide uptake in human OATP1B3 expressing HEK293/PDZK1 cells by scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217095Drug uptake in mouse hepatocytes at pH 5.52011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217083Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217112Inhibition of OATP1B1-mediated [3H]estrone-3-sulfate uptake in human OATP1B1 expressing HEK293/PDZK1 cells by scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID395496Aqueous solubility of the compound2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
The identification of orally bioavailable thrombopoietin agonists.
AID1217113Inhibition of OATP2B1-mediated [3H]estrone-3-sulfate uptake in human OATP2B1 expressing HEK293/PDZK1 cells by scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217109Drug uptake in mouse liver at 1 mg/kg, iv in presence of rifampicin OATP inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217064Inhibition of OCTN2-mediated [14C]carnitine uptake in human OCTN2 expressing HEK293/PDZK1 cells by scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217111Total clearance in pdzk1(-/-) mouse at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1282019Inhibition of human ERG channel tail current2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Emerging targets and new small molecule therapies in Parkinson's disease treatment.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1217101Drug uptake in mouse hepatocytes in presence of rifampicin OATP inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217077Tissue uptake clearance in bile duct cannulated Sprague-Dawley rat liver at 1 mg/kg, iv by by integration plot analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217091Drug uptake in mouse hepatocytes at 4 degC2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217107Drug uptake in mouse hepatocytes in presence of phenylalanine2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217108Maximum plasma concentration in mouse at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217094Drug uptake in mouse hepatocytes at pH 6.52011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217100Drug uptake in mouse hepatocytes in presence of taurocholate OATP inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207400Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID1217106Drug uptake in mouse hepatocytes in presence of GABA2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217099Drug uptake in mouse hepatocytes in presence of carbonyl cyanide-para-trifluoromethoxyphenylhydrazone ATP depletor2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217066Drug uptake in human OATP2B1 expressing HEK293/PDZK1 cells at 37 degC for 30 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207340Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1207280Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID1217110Total clearance in wild-type mouse at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217079Drug uptake in mouse kidney at 1 mg/kg, iv in presence of 30 umol/kg TPeA2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID349041Agonist activity at human thrombopoietin receptor expressed in mouse Ba/F3 cells by kinase activation based reporter gene assay relative to 30 ng/mL thrombopoietin2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.
AID1217092Solubility of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID387558Agonist activity at human thrombopoietin receptor in Ba/F3 cells assessed as activation of Stat5 response element-driven reporter gene expression2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.
AID1207523Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID1217088Clearance in bile-duct cannulated Sprague-Dawley rat bile with respect to plasma concentration at 1 mg/kg, iv for 6 to 8 hrs in presence of 20 mg/kg rifampicin (Rvb = 2.38 +/- 0.37 ml/h/kg)2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217084Clearance in Sprague-Dawley rat urine at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217096Drug uptake in mouse hepatocytes in absence of Na+2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217074Total clearance in bile duct cannulated Sprague-Dawley rat at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217065Drug uptake in human OATP1B1 expressing HEK293/PDZK1 cells at 37 degC for 30 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217067Drug uptake in human OCT1 expressing HEK293/PDZK1 cells at 37 degC for 30 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1871989Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID1207429Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID1217087Total clearance in Sprague-Dawley rat at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207557Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID1217070Drug metabolism in human urine assessed as oxidized metabolites at 50 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217078Drug uptake in mouse kidney at 1 mg/kg, iv in presence of 20 mg/kg OATP inhibitor rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217071Drug metabolism in human feces assessed as recovery at 50 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217063Inhibition of OCT1-mediated [14C]tetraethylammonium uptake in human OCT1 expressing HEK293/PDZK1 cells by scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID349040Agonist activity at human thrombopoietin receptor expressed in mouse Ba/F3 cells by kinase activation based reporter gene assay2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.
AID1217075Clearance in bile duct cannulated Sprague-Dawley rat bile at 1 mg/kg, iv after 6 to 8 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217068Drug uptake in human OATP1B3 expressing HEK293/PDZK1 cells at 37 degC for 30 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217090Drug uptake in mouse hepatocytes at 37 degC up to 5 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207494Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1217082Total clearance in bile-duct cannulated Sprague-Dawley rat at 1 mg/kg, iv in presence of 20 mg/kg rifampicin (Rvb = 34.3 +/- 3.9 ml/h/kg)2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217097Drug uptake in mouse hepatocytes in absence of Cl-2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID387559Agonist activity at human thrombopoietin receptor in Ba/F3 cells assessed as activation of Stat5 response element-driven reporter gene expression relative to 30 ng/mL thrombopoietin2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.
AID1217069Drug metabolism in human feces assessed as oxidized metabolites at 50 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217105Drug uptake in mouse hepatocytes in presence of verapamil2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1207369Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID1217085Distribution volume to the central compartment in Sprague-Dawley rat urine at 1 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1217076Drug uptake in mouse liver at 1 mg/kg, iv in presence of 30 umol/kg TPeA2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345468Human Thrombopoietin receptor (Prolactin receptor family)2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID18039863CLpro enzyme assay from Article 10.1101/2020.07.17.207019: \\Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.\\2020bioRxiv : the preprint server for biology, Aug-11Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1803987SARS-CoV-2 CPE assay from Article 10.1101/2020.07.17.207019: \\Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.\\2020bioRxiv : the preprint server for biology, Aug-11Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (687)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's53 (7.71)29.6817
2010's402 (58.52)24.3611
2020's232 (33.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials94 (13.18%)5.53%
Reviews147 (20.62%)6.00%
Case Studies140 (19.64%)4.05%
Observational16 (2.24%)0.25%
Other316 (44.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]